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ntry into mitosis in vertebrate cells is guarded by a
checkpoint that can be activated by a variety of insults,
including chromosomal damage and disrupting micro-
tubules (Rieder, C.L., and R.W. Cole. 1998. 
 
J. Cell Biol.
 
 142:
1013–1022; Rieder, C.L., and R.W. Cole. 2000. 
 
Curr. Biol.
 
10:1067–1070). This checkpoint acts at the end of inter-
phase to delay cells from entering mitosis, causing cells in
prophase to decondense their chromosomes and return to
G2 phase. Here, we show that in response to microtubule
poisons this “antephase” checkpoint is primarily mediated
by the p38 stress kinases and requires the Chfr protein that is
E
 
absent or inactive in several transformed cell lines (Scolnick,
D.M., and T.D. Halazonetis. 2000. 
 
Nature.
 
 406:430–435)
and lung tumors (Mizuno, K., H. Osada, H. Konishi, Y.
Tatematsu, Y. Yatabe, T. Mitsudomi, Y. Fujii, and T. Takahashi.
2002. 
 
Oncogene.
 
 21:2328–2333). Furthermore, in contrast
to previous reports, we ﬁnd that the checkpoint requires
ubiquitylation but not proteasome activity, which is in agree-
ment with the recent demonstration that Chfr conjugates
ubiquitin through lysine 63 and not lysine 48 (Bothos, J., M.K.
Summers, M. Venere, D.M. Scolnick, and T.D. Halazonetis.
2003. 
 
Oncogene.
 
 22:7101–7107).
 
Introduction
 
The decision to enter mitosis is not lightly made. There are
several distinct checkpoints that prevent mitosis when inter-
nal or external conditions are not favorable. The most
well-characterized checkpoints are triggered by unreplicated
or damaged DNA, which prevent mitosis by pathways de-
pendent on the ATM and ATR protein kinases. These
checkpoints block cells from entering mitosis by preventing
the Cdc25 phosphatases from activating the cyclin B1-Cdk1
kinase. Cyclin B1-Cdk1 is fully activated at the end of
prophase (Jackman et al., 2003), and this, along with nuclear
envelope breakdown in metazoans, correlates with irreversible
entry into mitosis. Thus, there are grounds to consider the
bulk of prophase not as part of mitosis but as the final part
of interphase. Moreover, a wide variety of insults in late G2
phase and early prophase will prevent cells from initiating
mitosis. Indeed, Bullough and Johnson (1951) coined the
term “antephase” to describe the period in late G2 phase,
just before the first visible signs of chromosome condensation
become evident, during which normal mouse epidermal cells
are reversibly delayed when subjected to stresses including
radiation damage, hypothermia, fluoride treatment, and lack
of microtubule function. Rieder and Cole (1998, 2000) fur-
ther showed that rat kangaroo, green monkey kidney, and
pig kidney cells in early prophase will transiently return to
antephase when they are exposed to cold, osmotic shock, or
microtubule poisons such as colcemid (for review see Pines
and Rieder, 2001; Mikhailov and Rieder, 2002). With the
agreement of Conly Rieder we will refer to this as the ante-
phase checkpoint to make clear that this acts at the end of
interphase and not in mitosis. This checkpoint is distinct
from the DNA damage checkpoint because it does not require
ATM or ATR (Rieder and Cole, 2000). It is also weakened
or absent in several tumors and transformed cell lines (Rieder
and Cole, 1998). The checkpoint is most easily assayed in early
prophase, during chromosome condensation, when colcemid
treatment is able to cause PtK1 cells in prophase to return to
antephase, but only before the nucleoli have broken down.
After the nucleoli have disassembled, colcemid is unable to
trigger the return to antephase and cells initiate mitosis
(Rieder and Cole, 1998). Nucleolar breakdown correlates
with the activation and nuclear translocation of cyclin B1-
Cdk1 and, therefore, could be considered one of the first
signs of entry into mitosis. At present, the mechanisms
behind the antephase checkpoint are ill defined.
One protein that has been suggested to be part of the an-
tephase checkpoint is Chfr (checkpoint protein with an
FHA domain and ring finger; Scolnick and Halazonetis,
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2000), a ubiquitin ligase that is down-regulated in several
cell lines through methylation of its promoter (Mizuno et
al., 2002). Chfr was originally reported to delay progress to
prometaphase in the presence of colcemid (Scolnick and
Halazonetis, 2000), and cells were surprisingly described as
delaying with high cyclin B1-Cdk1 activity (Scolnick and
Halazonetis, 2000), which conflicted with a role as part of
the antephase checkpoint because cyclin B1-Cdk1 is fully
activated only in late prophase. However, in 
 
Xenopus laevis 
 
ex-
tracts, Chfr is able to delay the activation of cyclin B-Cdk1,
apparently by targeting the Polo-like kinase, Plx, for degra-
dation by the proteasome (Kang et al., 2002), thereby pre-
venting the activation of the Cdc25 phosphatase that acti-
vates Cdk1. Chfr has also been reported to affect Polo-like
kinase levels in human cells in response to DNA damage
(Shtivelman, 2003). But whether Chfr does target Polo
for degradation or not is debatable because Chfr has
been shown to conjugate ubiquitin via its lysine 63 residue
(Bothos et al., 2003) that normally acts in signal transduc-
tion, especially for stress signals (Deng et al., 2000; Ulrich
and Jentsch, 2000; Hofmann and Pickart, 2001; Pickart,
2001; Wang et al., 2001), rather than to target proteins to
the proteasome.
The ability of a variety of stress stimuli to delay entry to
prophase might implicate the p38 stress-activated kinases
as components of the antephase checkpoint. Members of
the family of p38 kinases can be activated by a variety of
stresses (for review see Nebreda and Porras, 2000), and
some have been shown to be able to delay the cell cycle in
G1 and in G2 phase (for review see Bulavin et al., 2002).
In animal cells, the p38
 
 
 
 kinase has been reported to phos-
phorylate and inactivate the Cdc25B phosphatase in re-
sponse to UV damage in G2 phase (Bulavin et al., 2001),
thus delaying mitosis. p38
 
 
 
 has also been reported to be
part of the spindle assembly checkpoint that delays cells in
mitosis when chromosomes are not properly attached to
the spindle (Takenaka et al., 1998). However, until now
the stress kinases have not been shown to have a role in the
antephase checkpoint.
Here, we have investigated the mechanisms required for
the antephase checkpoint in mammalian cells. We show that
in response to microtubule poisons the checkpoint requires
the Chfr ubiquitin ligase, but not the proteasome, and that
Chfr does not delay mitosis by targeting Plk1 for degrada-
tion. Rather, we show that the microtubule-dependent an-
tephase checkpoint acts through the p38 kinases.
 
Results
 
Several transformed cell lines had been shown to lack the an-
tephase checkpoint (Rieder and Cole, 2000), and some of
these had also been described as lacking Chfr (Scolnick and
Halazonetis, 2000). Therefore, we were intrigued by the
possibility that the antephase checkpoint might require
Chfr. To investigate this possibility, we established two as-
says for the antephase checkpoint and compared PtK1 cells,
where the checkpoint was originally defined (Rieder and
Cole, 1998), with HeLa and U2OS cells that lack the check-
point (Rieder and Cole, 2000). Chfr is not expressed in
HeLa cells (Fig. 1 D) and is mutated in U2OS cells (Scol-
nick and Halazonetis, 2000). In our primary assay, we
identified cells in early to mid-prophase by DIC microscopy
using the criterion of discernible chromosome condensation
with an intact nucleolus (Fig. 1 A and Video 1, available at
http://www.jcb.org/cgi/content/full/jcb.200401139/DC1;
Rieder and Cole, 1998) and continually monitored the
response of the cells by time-lapse microscopy. When
prophase PtK1 cells were treated with nocodazole or colce-
mid and followed by time-lapse DIC microscopy, they de-
condensed their chromosomes after a variable period of time
and returned to antephase, which is illustrative of an intact
antephase checkpoint (Fig. 1 A and Video 1). These cells re-
mained in antephase for anywhere between 1 and 6 h (Fig. 1
E) before returning to mitosis (Video 1 and Fig. 1 F). In
contrast, HeLa cells and U2OS cells did not return to inter-
phase but continued on into mitosis (Fig. 1, B and C). In
agreement with Rieder and Cole’s (1998) original observa-
tions, PtK1 cells were unable to return to interphase once
the nucleoli began to disassemble, which, from our previous
studies on cyclin B1, is the time when cyclin B1 is activated
and moves into the nucleus (Furuno et al., 1999; Jackman et
al., 2003). To corroborate these results, we used a second as-
say according to Rieder and Cole (2000). We treated a pop-
ulation of PtK1 cells with nocodazole or colcemid and, at
various times after treatment, stained the cells with Hoechst
33342 and determined the proportion of cells at each stage
of mitosis by fluorescence microscopy. We confirmed that
cells with an intact antephase checkpoint show a marked de-
crease in the number of cells in prophase after drug treat-
ment (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200401139/DC1).
 
Chfr is required for the antephase checkpoint triggered 
by microtubule poisons
 
To determine if Chfr was required for the antephase check-
point we generated a dominant-negative mutant by delet-
ing the FHA domain from Chfr (Scolnick and Halazonetis,
2000). When injected into PtK1 cells, the mutant but not
the wild-type protein abrogated the antephase checkpoint;
early prophase cells no longer returned to interphase after
treatment with nocodazole or colcemid but continued on
to breakdown their nuclear envelope (Fig. 2 A, Table I,
and Video 2, available at http://www.jcb.org/cgi/content/
full/jcb.200401139/DC1). Some cells arrested in prophase
and were separately scored (Table I). As a more direct test
for whether or not Chfr was required for the antephase
checkpoint, we generated cell lines in which Chfr was ex-
pressed under an inducible promoter (the tet-off system).
We used U2OS cells as the parental cell line, as in U2OS
cells the endogenous Chfr is inactive due to a point mu-
tation in the carboxyl-terminus (Scolnick and Halazone-
tis, 2000). We isolated clones of cells that on an immuno-
blot expressed approximately equivalent levels of wild-type
Chfr or Chfr with a mutation in the RING finger to dis-
able its ubiquitylation activity (Fig. 2 B). Immunofluores-
cence analysis showed that most individual cells expressed
similar levels of the proteins (Fig. 2 C), and that at least 50
and 80% of the cells in the population expressed wild-type 
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or mutant Chfr, respectively. We found that cells express-
ing wild-type Chfr were able to return to interphase after
challenging with colcemid in early prophase, whereas the
uninduced cells and cells expressing the inactive Chfr
mutant continued on to mitosis (Fig. 2 D and Videos 3
and 4, available at http://www.jcb.org/cgi/content/full/
jcb.200401139/DC1). The cells were fixed and stained af-
ter the assays to show that they were expressing the ectopic
Chfr protein (Fig. 2 D and Videos 3 and 4). We also syn-
chronized cells expressing wild-type Chfr in S phase, and
used time-lapse microscopy to compare their entry into
mitosis with and without colcemid treatment in G2 phase.
This comparison showed that colcemid delayed mitosis by
an average of 3 h in a substantial proportion of the cells
(Fig. 2 E). Thus, Chfr is able to restore the microtubule-
dependent antephase checkpoint.
 
The antephase checkpoint requires ubiquitylation but 
not proteasome activity
 
Chfr had been reported to ubiquitylate and target for de-
struction the Polo-like kinase in 
 
X. laevis 
 
cycling extracts,
thereby delaying the activation of cyclin B-CDK1 (Kang et
al., 2002). Therefore, we assayed whether or not Plk1 pro-
teolysis was involved in the antephase checkpoint in mam-
malian somatic cells. However, we were unable to detect
any loss of Plk1 upon activation of the antephase check-
point, either by immunofluorescence analysis (not de-
picted) or by quantifying the level of a Plk1-GFP fusion
protein in living cells (Fig. 3 A). (This Plk1-GFP fusion
protein mimics the endogenous protein because it is de-
graded at the end of mitosis [Lindon and Pines, 2004].)
Moreover, we found that the antephase checkpoint did
not require proteasome-dependent degradation. Prophase
Figure 1. Assay for the antephase check-
point. DIC images of a Ptk1 (A), HeLa 
(B), and U2OS (C) cell in early prophase, 
identified by partial chromosome con-
densation. Cells were treated with 15  M 
colcemid at 0 min (top panels). Approxi-
mately 20 to 100 min after treatment, 
Ptk1 cells decondensed their chromo-
somes and returned to antephase, whereas 
Hela and U2OS cells continued into 
mitosis (bottom panels). After a variable 
time with decondensed chromosomes, 
the PtK1 cells returned to prophase and 
subsequently reentered mitosis (A; Video 
1). Cells are representative of more than 
six Ptk1, eight HeLa, and nine U2OS 
cells in 12 different experiments. Bar, 10 
 m. The complete series of images for 
the Ptk1 cell are presented in Quicktime 
format as Video 1, available at http://
www.jcb.org/cgi/content/full/
jcb.200401139/DC1. (D) HeLa cells 
do not express Chfr. (lane 1) Anti-Chfr 
immunoblot of whole cell lysates from 
HeLa cells; (lane 2) HeLa cells transfected 
with Chfr under the CMV promoter; 
(lane 3) normal diploid fibroblasts. Equal 
amounts of protein were loaded per lane. 
Molecular mass markers are indicated 
on the left. (E) Duration of antephase 
delay. The time between initial chromo-
some decondensation and subsequent 
return to prophase (visible chromosome 
condensation) was measured for five 
PtK1 cells from the time-lapse videos. 
(F) Schematic timeline of the antephase 
checkpoint. 
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Although polyubiquitinated proteins are often targeted for
destruction by the proteasome, they have also been shown to
act as signaling molecules, especially when conjugated via
K63. Moreover, Chfr has been characterized as a ubiqui-
tin ligase that requires Ubc13-Mms2 (Bothos et al., 2003),
a dimeric ubiquitin-conjugating enzyme that preferentially
conjugates ubiquitin through its K63 and not K48 residue.
To test whether or not the antephase checkpoint required
ubiquitylation, we injected methyl-ubiquitin into cells to
block ubiquitylation. This treatment abrogated the ante-
Figure 2. Chfr is required for the antephase check-
point. (A) Fluorescence (top right) and DIC images 
of Ptk1 cell expressing a GFP tagged  FHA mutant 
of Chfr. The cell was treated with 15  M colcemid at 
0 min (top left) and continued on into mitosis (bottom 
panels). The complete series of DIC images are pre-
sented in Quicktime format as Video 2. (B) Anti-Chfr 
immunoblot of tetracycline-inducible Chfr cell lines. 
(lane 1) Uninduced cells; (lane 2) cells expressing 
epitope-tagged wild-type Chfr; (lane 3) cells expressing 
epitope-tagged RING-finger mutant of Chfr. Epitope-
tagged Chfr is marked by the arrowhead, endogenous 
Chfr is marked by the arrow. Molecular mass markers 
are indicated on the left. (C) Box plot of the relative 
fluorescence intensities of individual U2OS cells of 
the stable cell lines expressing inducible Chfr proteins. 
Cells were stained with anti-Xpress epitope antibody 
to detect wild type (wt, n   15) or the Ring finger mutant 
(RING, n   16) of Chfr. (D) DIC images of U2OS cell 
lines expressing an inducible wild type (left) or a 
RING finger mutant (right) of Chfr were treated with 
15  M colcemid at 0 min (top). Cells expressing 
wild-type Chfr decondensed their chromosomes and 
returned to antephase for least 3.5 h (middle left). In 
contrast, cells expressing mutant Chfr continued on 
into mitosis (middle right). Cells were then fixed and 
stained with anti-Xpress tag antibody to assay for ex-
pression of the ectopic Chfr (bottom). Bar, 10  m. The 
complete series of images are presented in Quicktime 
format for the cell expressing wild-type Chfr as Video 3 
and for the RING finger mutant as Video 4. (E) Colcemid 
delays mitosis in U2OS cells expressing wild-type 
Chfr. Synchronized U2OS cells expressing wild-type 
Chfr from an inducible promoter were treated or not with 
15  M colcemid in G2 phase. Cells were monitored 
by time-lapse microscopy, and the time at which they 
broke down their nuclear envelopes was plotted as a 
frequency histogram. Cells are representative of two 
separate experiments. Videos are available at http://
www.jcb.org/cgi/content/full/jcb.200401139/DC1.
 
PtK1 cells treated with the specific proteasome inhibitors
MG132 or epoxomicin returned to interphase after treat-
ment with nocodazole or colcemid, which is indicative of a
functional checkpoint (Table II). In these experiments,
MG132 and epoxomicin did block protein degradation
because prophase cells treated with these compounds with-
out nocodazole subsequently arrested in metaphase. Thus,
mammalian cells appeared to differ from 
 
X. laevis 
 
extracts
where proteasome inhibitors blocked the ability of Chfr to
inhibit mitosis (Kang et al., 2002). 
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phase checkpoint in 4 out of 8 cells, which carried on into
mitosis (3 other cells arrested in prophase), whereas injecting
wild-type ubiquitin allowed 8 out of 10 cells to return to in-
terphase when challenged with colcemid (Fig. 3 B and Table
II). Thus, the antephase checkpoint appeared to require
ubiquitylation but not proteasome-dependent proteolysis.
 
The p38 stress kinase is required for the 
antephase checkpoint
 
Ubiquitylation through K63 has been shown to activate the
stress kinase pathway through the TAK1 kinase in response
to interleukin-1 (Wang et al., 2001). In addition, cells
treated with low doses of anisomycin have a reduced mitotic
index (Lindon, C., personal communication). Anisomycin
has been shown to be a potent activator of p38 stress kinases
(Cano et al., 1994), and p38 kinases can also be activated by
treating late G2/mitotic cells with nocodazole (Takenaka et
al., 1998). Therefore, we analyzed if the p38 kinases could
play a part in the antephase checkpoint. We found that ani-
somycin was as effective as nocodazole or colcemid in both
reducing the number of prophase cells in the population
(supplemental material) and causing mid-prophase cells to
return to interphase (Fig. 4 A and Video 5, available at
http://www.jcb.org/cgi/content/full/jcb.200401139/DC1).
Treatment with other stimuli known to activate the p38
kinases such as 5 
 
 
 
M H
 
2
 
O
 
2
 
 or 10 j/m
 
2
 
 UV also caused a
decline in the number of prophase cells (supplemental ma-
terial). To support a role for the p38 stress kinases, we com-
pared the effects of the p38
 
 
 
 and 
 
 
 
 kinase inhibitors
SB203580 and SB202190, with the inactive compound
SB202474 as a control. In both of our assays, SB203580
and SB202190 abrogated the antephase checkpoint induced
by colcemid, whereas SB202474 had no effect (Fig. 4 B and
supplemental material). In these experiments, cells treated
with colcemid subsequently arrested for several hours in
 
Table I. 
 
Induction of the antephase checkpoint in PtK1 cells
Challenge
Return to
interphase
Continue to
mitosis
Arrest in
prophase
 
Cells expressing wild-type Chfr
Colcemid 5 0 2
Cells expressing 
 
 
 
FHA-Chfr
Challenge
Return to
interphase
Continue to
mitosis
Arrest in
prophase
Colcemid 0 7 5
Anisomycin 5 1 0
Inject p38
 
 
 
41 2
PtK1 cells expressing wild type or 
 
 
 
FHA-Chfr were treated as described and
their behavior was assayed by time-lapse DIC microscopy. Cells that
decondensed their chromosomes were scored as returning to interphase,
and cells that broke down their nuclear envelopes were scored as
continuing to mitosis.
Figure 3. Ubiquitylation but not proteasome-dependent degradation 
is required for the antephase checkpoint. (A) Plk1 is not degraded by 
the antephase checkpoint. Ptk1 cells were injected with an expression 
construct encoding YFP fused to Plk1 and followed by time-lapse 
fluorescence and DIC microscopy at 3-min intervals. In early prophase, 
the cell was treated with 15  M colcemid and the cell returned to 
antephase. The total cell fluorescence minus background was quan-
tified for each cell in successive images of a time series and plotted 
over time. Graph is from a cell representative of three cells in four 
independent experiments. (B) Ubiquitylation is required for the 
antephase checkpoint. DIC images of PtK1 cells injected with wild 
type (top) or methylated ubiquitin (bottom) in early prophase and 
then treated with 15  M colcemid at 0 min. Cells with wild-type 
ubiquitin returned to antephase, whereas cells injected with methyl-
ated ubiquitin continued into mitosis. Cells are representative of 8 
out of 10 wild type and 4 out of 8 methylated ubiquitin-injected cells 
in three independent experiments. Bar, 10  m.
 
Table II. 
 
Effect of ubiquitin and the proteasome on the
antephase checkpoint
Treatment
Return to
interphase
Continue to
mitosis
Arrest in
prophase
 
Ubiquitin 8 1 1
Methyl-ubiquitin 1 4 3
MG132 12 2 4
Epoxomicin 4 1 1
PtK1 cells were treated as described and their behavior was assayed by
time-lapse DIC microscopy. Cells that decondensed their chromosomes
were scored as returning to interphase, and cells that broke down their
nuclear envelopes were scored as continuing to mitosis. 
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prometaphase in the presence or absence of p38 inhibitors,
which is indicative of an intact spindle assembly checkpoint.
These results strongly indicated that the p38 
 
 
 
 and/or 
 
 
 
kinases were necessary for the antephase checkpoint. How-
ever, although SB203580 and SB202190 had been shown to
be highly specific inhibitors of p38 in vitro, they could have
acted by inhibiting another, related kinase in vivo. To elimi-
nate this possibility, we injected active p38 kinases into early
prophase PtK1 cells and found that either p38
 
 
 
 or p38
 
 
 
forced the majority of cells to return to interphase, whereas
p38
 
 
 
 did not (Fig. 4 C and Table III). Injecting the related
MAP kinase family member, Erk2, had no effect on progres-
sion through prophase (Fig. 4 C and Table III). Thus, we
concluded that the p38
 
 
 
 and 
 
 
 
 stress kinases were impor-
tant components of the antephase checkpoint.
To discriminate between whether the p38 kinases lay up
or downstream of Chfr, we treated U2OS cells, which have a
mutant Chfr, with 50 ng/ml anisomycin for 30 min to acti-
vate the p38 stress kinases and followed their entry into mi-
tosis by time-lapse microscopy. Anisomycin blocked the ap-
pearance of prophase cells within 30 min and delayed entry
to mitosis in the majority of the population by an average of
90 min, indicating that U2OS cells might have some of the
components necessary for the antephase checkpoint (Fig. 5
A). However, the decline in mitotic cells might have been
caused by cells arresting in late G2 phase, and we wished to
determine whether or not anisomycin could cause cells to re-
turn from prophase to antephase. Therefore, we monitored
the behavior of the centrosomes in HeLa cells expressing
 
 
 
-tubulin-YFP, which normally accumulated on centrosomes
in early prophase (Khodjakov and Rieder, 1999; Fig. 5 B
and Video 6, available at http://www.jcb.org/cgi/content/
full/jcb.200401139/DC1), and found that anisomycin was
able to reverse this recruitment (Fig. 5 C and Video 7, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200401139/
DC1). Thus, even in the absence of a functional Chfr pro-
tein, activating the p38 kinases appeared to be able to medi-
ate the antephase checkpoint.
One interpretation of these results was that Chfr was re-
quired to activate p38 when cells were treated with no-
codazole. To test this interpretation, we abrogated the an-
tephase checkpoint in PtK1 cells by expressing the 
 
 
 
FHA
mutant of Chfr. When challenged with anisomycin or in-
jected with active p38 kinase the cells returned to inter-
Figure 4. p38 stress kinases are required for the antephase check-
point. (A) DIC images of Ptk1 cells in early prophase before (left) or 
after (right) treatment with 50 ng/ml anisomycin. The complete series 
of images for the cell treated with anisomycin are presented in 
Quicktime format as Video 5, available at http://www.jcb.org/cgi/
content/full/jcb.200401139/DC1. (B) DIC images of Ptk1 cells in 
early prophase that were treated at 0 min with 15  M colcemid plus 
5  M SB203580 (top), or 15  M colcemid plus 5  M SB202474 
(bottom) and followed by time-lapse microscopy. Cells with the 
active p38 inhibitor (SB203580) continued into mitosis. Cells are 
representative of four cells in two experiments for each SB compound. 
(C) Ptk1 cells in early prophase were injected with active p38  (top) 
or active ERK2 (bottom) and followed by time-lapse DIC microscopy 
at 3-min intervals. The cell injected with p38 returned to antephase. 
Bars, 10  m.
 
Table III. 
 
Effect of stress kinases and cyclin A–Cdk kinases on the 
antephase checkpoint
Protein injected
Return to
interphase
Continue to
mitosis
Arrest in
prophase
 
GST-p38
 
 
 
61 0
p38
 
 
 
63 0
p38
 
 
 
72 1
p38
 
 
 
15 4
Cyclin A–CDK2
 
AF
 
09 4
Cyclin A–CDK2 7 4 3
PtK1 cells were injected with the proteins as described and their behavior
was assayed by time-lapse DIC microscopy. Cells that decondensed their
chromosomes were scored as returning to interphase, and cells that broke
down their nuclear envelopes were scored as continuing to mitosis. 
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phase (Fig. 5 D and Table I), indicating that p38 was likely
to be downstream of Chfr.
 
Active cyclin A–CDK2 kinase can overcome the 
antephase checkpoint
 
Lastly, we considered the possible mechanisms by which
the p38 kinases might reverse progress through prophase.
We had previously shown that cyclin A–dependent kinase
activity was important for cells to enter and progress
through prophase (Furuno et al., 1999) and that cyclin B1-
Cdk1 kinase was significantly activated only towards the
end of prophase (Jackman et al., 2003). Thus, it was possi-
ble that p38 kinases blocked or reversed cells in early
prophase by inhibiting cyclin A–dependent kinases, per-
haps by inactivating the Cdc25 phosphatases. If inactiva-
tion of cyclin A–Cdk complexes was required for the an-
tephase checkpoint, we reasoned that cyclin A in a complex
with a mutant form of Cdk that could not be inactivated
by phosphorylation should overcome the checkpoint. In
support of this reasoning, when we injected cells with cy-
clin A bound to a mutant form of CDK2 that could not be
phosphorylated and inhibited (CDK2
 
AF
 
), 13 out of 13 in-
jected cells were no longer able to return to antephase when
challenged with colcemid in prophase (Fig. 6 and Table
III). As a control, we injected cells with wild-type CDK2
and cyclin A. In this case, 7 out of 14 prophase cells still re-
turned to antephase after being challenged with colcemid
(Table III).
Figure 5. p38 is downstream of Chfr. 
(A) Anisomycin treatment delays entry 
into mitosis. Synchronized U2OS cells 
were treated or not in G2 phase with 
anisomycin for 30 min, and then followed 
by time-lapse DIC microscopy at 3-min 
intervals, and the time when the cell 
completed nuclear envelope breakdown 
was assayed and plotted as a frequency 
histogram. Cells are representative of 
three different experiments. (B and C) 
HeLa cells stably expressing  -tubulin-
EYFP were followed by time-lapse DIC 
and fluorescence microscopy at 3-min 
interval. 29 z-sections spaced 0.4  m 
apart were taken for each time point, 
deconvolved, and used to generate a 
maximum intensity projection at each 
time point. In untreated cells (B),  -tubulin 
accumulated on centrosomes in prophase 
just before nuclear envelope breakdown 
(the complete series of images are pre-
sented in Quicktime format as Video 6). 
The accumulation of  -tubulin on cen-
trosomes was reversed when the cell 
was treated with 1  g/ml anisomycin. 
The complete series of images are pre-
sented in Quicktime format as Video 7. 
(D) Fluorescence (top) and DIC images 
of a Ptk1 cell expressing dominant-
negative GFP-Chfr. The cell was injected 
in early prophase (time 0) with active 
p38  and followed by time-lapse DIC 
and fluorescence microscopy at 3-min 
intervals as it returned to antephase. The 
cell is representative of four cells in 
seven experiments. Bar, 10  m. Videos 
are available at http://www.jcb.org/cgi/
content/full/jcb.200401139/DC1. 
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Discussion
 
Here, we have shown that the Chfr protein is an important
component of the antephase checkpoint in mammalian cells
and that the p38 stress kinases appear to be downstream ef-
fectors of the checkpoint. As part of the checkpoint mecha-
nism, Chfr requires its ubiquitin ligase activity, but its sub-
strates do not need to be degraded by the proteasome. This
is the first direct demonstration of a link between Chfr and
the antephase checkpoint; originally Chfr was reported to be
required for a checkpoint that prevented entry to metaphase
after cyclin B1-Cdk1 is activated (Scolnick and Halazonetis,
2000). However, our evidence indicates that Chfr is re-
quired for the antephase checkpoint, and, in agreement with
Rieder and Cole (1998), we find that cells no longer respond
to the antephase checkpoint when the nucleoli begin to
breakdown, which is the time when significant amounts of
active cyclin B1 first appear in the cell and move into the
nucleus (Jackman et al., 2003). We also find that active cy-
clin A–Cdk complexes can override the checkpoint, indicat-
ing that cyclin A–Cdks may be targets of the checkpoint.
At present, we are unable to explain exactly how Chfr acts
in the checkpoint. Clearly, Chfr must be acting as an ubiq-
uitin ligase because wild-type Chfr, but not a RING finger
mutant, is able to restore the antephase checkpoint in U2OS
cells. Moreover, methylated ubiquitin, which blocks poly-
ubiquitylation, abolishes the checkpoint. In contrast to 
 
X.
laevis 
 
extracts, in mammalian cells Chfr does not need to tar-
get its substrates for proteasome-dependent degradation to
block progress into mitosis because the checkpoint is unaf-
fected by proteasome inhibitors. Thus, we believe that Chfr
acts in a signaling pathway by generating ubiquitin chains
that are conjugated through K63. In support of this belief,
we find that Chfr binds to Ubc13 in a yeast 2 hybrid assay,
and in collaboration with J. Chen (personal communica-
tion), we have found that Chfr requires Ubc13 to autoubiq-
uitylate (unpublished data). This finding is in agreement
with the recent report that Chfr auto-ubiquitylates through
K63 (Bothos et al., 2003). One intriguing possibility is that
Chfr could activate the p38 stress kinase pathway by activat-
ing the TAK1 kinase. TAK1 is a MAP kinase kinase kinase
in the p38 kinase pathway and can be activated by the
TRAF6 ubiquitin ligase in response to interferon (Wang et
al., 2001). Indeed, in a yeast 2 hybrid screen we have iso-
lated the T6BP (TRAF6 binding protein) protein, which in-
teracted with Chfr in a RING finger-dependent manner
(unpublished data). T6BP is a protein that can interact with
the TRAF6 protein (Ling and Goeddel, 2000). This finding
raises the possibility that Chfr in combination with T6BP
might be able to activate TAK1 in response to microtubule
depolymerization. However, as yet, we have been unable
biochemically to confirm this model.
Our evidence indicates that the p38 stress kinases are re-
quired to effect the antephase checkpoint and that they ap-
pear to act downstream or in parallel to Chfr. Chemical in-
hibitors of the p38
 
 
 
 and 
 
 
 
 kinases abrogate the antephase
checkpoint, and an active form of p38
 
 
 
, but not p38
 
 
 
 or
the related ERK2 kinase, is able to return early prophase
cells to interphase. In animal cells, the p38 stress kinases
have previously been implicated in two different late cell cy-
cle checkpoints: in G2 phase (Bulavin et al., 2001) and in
mitosis itself (Takenaka et al., 1998). Bulavin et al. (2001)
showed that, in vitro, the p38 stress kinases are able to phos-
phorylate the Cdc25B phosphatase that can play a role in
the initiation of mitosis, and that this may underlie the G2
arrest in response to UV damage (Bulavin et al., 2001). This
mechanism may also be the means by which the p38 stress
Figure 6. Active cyclin A–Cdk2 complexes override the 
antephase checkpoint. DIC images of Ptk1 cells. Cells in 
early prophase were injected with cyclin A bound to either 
wild-type Cdk2 (top) or a Cdk2 T14A/Y15F mutant (bottom) 
that cannot be inactivated by phosphorylation. 5 min after 
injection, the cells were treated with 15  M colcemid 
(0 min) and followed by time-lapse microscopy. Some 
cells arrested in prophase and were scored separately. 
Cells are representative of 9 mutant and 7 wild-type 
Cdk-injected cells in 14 independent experiments. Bar, 
10  m. 
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kinases are able to return prophase cells to interphase, and
we show that cyclin A in a complex with a form of CDK2
that is independent of Cdc25 is able to overcome the an-
tephase checkpoint. However, as yet, we have been unable to
detect biochemically a change in the phosphorylation state
of CDK2 bound to cyclin A when we activate the antephase
checkpoint, nor when we activate the p38 kinases directly
with anisomycin (Koop, L., personal communication; un-
published data), although this may simply reflect the practi-
cal difficulty in obtaining sufficient numbers of cells in late
G2/early prophase.
Takenaka et al. (1998) reported that the p38 stress kinases
are required to arrest mammalian cells in prometaphase
when microtubules are destabilized with nocodazole. Thus,
they implicated the p38 stress kinases as important compo-
nents of the spindle assembly checkpoint. In fission yeast,
the p38 stress kinase has been reported to be a component of
a checkpoint required to arrest cells in mitosis when the
spindle is misoriented (Gachet et al., 2001). However, we
were unable to detect any change in the ability of cells to ar-
rest in mitosis in response to nocodazole in the presence or
absence of p38 kinase inhibitors. At present, we are unable
to explain the apparent discrepancy in our results from those
of Takenaka et al. (1998), although one difference in experi-
mental protocols is that we assayed mitotic arrest by count-
ing cells stained with Hoechst 33342, whereas Takenaka et
al. (1998) assayed arrest more indirectly by measuring H1
kinase activity in cell lysates.
Chfr is inactivated or absent from several cell lines
(Scolnick and Halazonetis, 2000) and tumors (Mizuno et
al., 2002), perhaps indicating that the loss of Chfr may con-
fer a growth advantage, at least in cell culture. Our results
could be interpreted as showing that cells lacking Chfr have
a lesion in at least one stress response pathway, which might
be an advantage in a tumor environment. However, we find
that these cells still delay division in response to UV (unpub-
lished data) or H
 
2
 
O
 
2
 
 treatment, making it less likely that the
advantage conferred by the loss of Chfr is the ability to di-
vide in low O
 
2
 
 tension environments. Nevertheless, Chfr
may potentially link perturbations in the cytoskeleton to the
stress kinase pathway and indicate that other ubiquitin li-
gases may function in a similar role to block entry into mito-
sis in response to other forms of stress (Fig. 7).
 
Materials and methods
 
Cell culture, synchronization, and drug treatments
 
HeLa and U2OS cells were cultured and synchronized as described previ-
ously (Jackman et al., 2003). Cell lines expressing inducible Chfr were cul-
tured in DME plus 5% FBS, 5% newborn calf serum, 100 U/ml penicillin,
0.1 mg/ml streptomycin, 0.292 mg/ml glutamine, 1% (vol/vol) Fungizone
(GIBCO BRL), 0.25 mg/ml hygromycin B, 1 
 
 
 
g/ml tetracycline, and 0.5
mg/ml geneticin at 37
 
 
 
C/5% CO
 
2
 
. Ptk1 cells were cultured in Ham’s F-12
medium (GIBCO BRL), 10% FBS, 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin, 1 mM Na pyruvate, and 0.1% (vol/vol) Fungizone (GIBCO BRL) at
37
 
 
 
C/5% CO
 
2
 
. Colcemid was added to a final concentration of 15 
 
 
 
M,
anisomycin to 50 ng/ml, SB203580 and SB202474 (Calbiochem) to 5 
 
 
 
M,
H
 
2
 
O
 
2
 
 to 0.0 2 mM, MG-132 to 42 nM, MG-115 (Calbiochem) to 50 nM,
and epoxomicin (Calbiochem) to 10 
 
 
 
M.
 
Protein expression, purification, and injection
 
Cyclin A–Cdk2 and cyclin A–Cdk2AF were expressed in and purified from
 
Escherichia coli
 
 BL21 cells as described previously (Brown et al., 1999).
Proteins were 
 
 
 
90% pure on Coomassie blue R250–stained gels. Proteins
were concentrated in injection buffer (12.5 mM Tris-HCl, pH 8.0, 200 mM
NaCl, 2.5 mM DTT, and 1 mM EGTA) in a Vivaspin 5,000 MW cut-off mi-
croconcentrator (Vivascience). Approximately 5% of the cell volume was
injected into cells using a semiautomatic microinjector (Eppendorf) at-
tached to a microscope (model DMIRBE; Leica). p38
 
 
 
, p38
 
 
 
, and p38
 
 
were gifts of C. Smythe (University of Sheffield, Sheffield, UK). Ubiquitin
(50 mg/ml) and methylated ubiquitin were purchased from Calbiochem.
Figure 7. Schematic for the antephase checkpoint. Several different insults are able to block cells in antephase, some or all of which may act 
through the p38 stress kinases. The Chfr protein appears to be required to activate the checkpoint in response to microtubule poisons but not to 
UV or H2O2 and probably signals through ubiquitin conjugation, perhaps through the TAK1 kinase. Note that this is only a tentative model.516 The Journal of Cell Biology | Volume 166, Number 4, 2004
Antephase checkpoint assay
For live cell assay, cells were cultured on 0.15-mm  T dishes (Bioptechs) at
37 C, treated with the drugs colcemid (15  M) or anisomycin (50 ng/ml),
and followed by time-lapse DIC microscopy at 3-min intervals. Early
prophase PtK1 cells were identified by the beginnings of chromosome con-
densation. U2OS cells were treated 11 h after release from a double thymi-
dine block to increase the number of mitotic cells. When treated with 50
ng/ml anisomycin 30 min after the addition of the drug, the U2OS cultures
were washed with fresh prewarmed medium six times and then followed by
DIC microscopy. At least 200 cells were examined for each experiment,
scored for nuclear envelope breakdown, and plotted on a graph.
Image acquisition
Images were acquired using a microscope and a 40  1.0 NA or 63  1.35
NA oil immersion objective as described previously (Karlsson and Pines,
1998) with the addition of a motorized XY stage (Prior Scientific) to visual-
ize multiple fields of cells per time point. Images were taken with a cooled
CCD camera (model Pentamax or Micromax; Roper Scientific) using IP
Lab software (Scanalytics) and analyzed using ImageJ software (National
Institutes of Health) before exporting to Adobe Photoshop for printing or
Adobe Premiere to generate the Quicktime videos. The four-dimensional
imaging of  -tubulin YFP cells were imaged at 37 C on a microscope
(model DeltaVision Spectris; Applied Precision) equipped with a 40  1.35
NA lens (Olympus) and a cooled CCD camera (model CoolSnap HQ;
Roper Scientific). Stacks of 29 z-images 0.4  m apart were taken every 3
min, and the maximum intensity projections were combined using Soft-
Worx
TM software for the images and videos in Fig. 5.
Immunofluorescence
To detect epitope-tagged Chfr, cells were fixed and permeabilized with 50:
50 vol/vol MeOH/Acetone and stained with anti-Xpress antibody (Invitro-
gen) at 1:2,000 dilution followed by an Alexa Fluor 488–labeled anti–
mouse secondary antibody (Molecular Probes).
Fixed cell assay for prophase checkpoint
15   M colcemid, 1  g/ml anisomycin, 15  M colcemid plus 5  M
SB203580, 15  M colcemid plus 5  M SB202474, or their carrier DMSO
were directly added to the medium of cells growing on glass coverslips. At
0, 60, and 120 min after drug treatment, coverslips were removed from
medium and fixed with 3% PFA in 1  PBS. Cultures were stained with
Hoechst 33342. Coverslips were examined and mitotic cells were scored
by epifluorescence using a microscope (model Optiphot; Nikon) equipped
with a 20  0.75 NA and a 40  1.3 NA lens (Nikon).
Online supplemental material
A fixed cell assay showing that p38 kinases are required for the antephase
checkpoint is shown in Fig. S1. Video 1 shows live cell imaging of the
antephase checkpoint. Video 2 shows that  FHA Chfr abrogates the an-
tephase checkpoint. Video 3 shows that wild-type Chfr rescues the an-
tephase checkpoint in U2OS cells. Video 4 shows that the Ring finger
mutant of Chfr fails to rescue an antephase checkpoint defect. Video 5
shows that anisomycin can activate the antephase checkpoint. Video 6
shows live cell imaging of HeLa cells stably expressing  -tubulin-EYFP.
Video 7 shows that anisomycin reverses the accumulation of  -tubulin
on centrosomes. Online supplemental material is available at http://
www.jcb.org/cgi/content/full/jcb.200401139/DC1.
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